Immunovant Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. Headquartered in Durham, North Carolina and founded in 2018, the company specializes in immunology and leverages anti-FcRn (neonatal Fc receptor) technology to modulate immunoglobulin G (IgG) levels in the body. Its pipeline includes investigational monoclonal antibody candidates such as batoclimab and IMVT-1402, designed to selectively target FcRn and potentially address a range of autoimmune conditions driven by pathogenic antibodies. Immunovant concentrates on creating targeted, subcutaneous treatments that can be administered in outpatient settings, aiming to provide options that fit into patients’ daily lives. Within the healthcare and biotechnology sector, Immunovant plays a role as an innovator in FcRn inhibition, collaborating closely with clinicians, regulators, and research partners to advance its clinical programs and generate data across multiple autoimmune indications.